Patents Examined by Amanda L Aguirre
  • Patent number: 11597737
    Abstract: Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: March 7, 2023
    Assignee: University of South Carolina
    Inventors: Campbell McInnes, Sandra Navonne Craig
  • Patent number: 11578083
    Abstract: The present invention relates to pyrimidinium compounds of formula (I), to the stereoisomers, salts, tautomers and N-oxides thereof, their mixtures and to compositions comprising such compounds or mixtures. The invention also relates to methods and uses of these pyrimidinium compounds and of compositions thereof, for combating and controlling animal pests. Furthermore, the invention relates also to pesticidal methods of applying such substituted pyrimidinium compounds. The pyrimidinium compounds of the present invention are defined by the following general formula (I): wherein R1, R2 and Het are defined as in the description.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: February 14, 2023
    Assignee: BASF SE
    Inventors: Joachim Dickhaut, Ashokkumar Adisechan, Gopal Krishna Datta, Olesya Kuzmina, Juergen Langewald
  • Patent number: 11566006
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 31, 2023
    Assignee: Pfizer Inc.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Patent number: 11548854
    Abstract: The present application relates to the use of heterocyclic compounds for controlling animal pests including arthropods, insects and nematodes, to novel heterocyclic compounds, to processes for their preparation and to intermediates for preparing the heterocyclic compounds.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 10, 2023
    Inventors: Eike Kevin Heilmann, Joerg Greul, Axel Trautwein, Hans-Georg Schwarz, Isabelle Adelt, Roland Andree, Peter Luemmen, Maike Hink, Martin Adamczewski, Mark Drewes, Angela Becker, Arnd Voerste, Ulrich Goergens, Kerstin Ilg, Johannes-Rudolf Jansen, Daniela Portz
  • Patent number: 11540517
    Abstract: The present invention relates to novel active compound combinations comprising at least one known compound of the formula (I) and at least one further active compound, which combinations are highly suitable for controlling animal and microbial pests such as unwanted insects and/or unwanted acarids and/or unwanted nematodes.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: January 3, 2023
    Inventors: Silvia Cerezo-Galvez, Christian Marienhagen, Holger Weckwert, Wolfgang Thielert, Marita John
  • Patent number: 11512071
    Abstract: Methods described herein enable the production of numerous molecular species through decarboxylative cross-coupling via use of photoredox and transition metal catalysts. For example, methods described herein enable the production of numerous molecular species through decarboxylative cross-coupling via use of photoredox and transition metal catalysts. A method described herein, in some embodiments, comprises providing a reaction mixture including a photoredox catalyst, a transition metal catalyst, a coupling partner and a substrate having a carboxyl group. The reaction mixture is irradiated with a radiation source resulting in cross-coupling of the substrate and coupling partner via a mechanism including decarboxylation, wherein the coupling partner is selected from the group consisting of a substituted aromatic compound and a substituted aliphatic compound.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: November 29, 2022
    Inventors: David W. C. MacMillan, Zhiwei Zuo
  • Patent number: 11510899
    Abstract: Provided is a method for treating a symptom of vibrio infection by using an RTX toxin production inhibitor comprising N-(4-oxo-4H-thieno[3,4-c]chromen-3-yl)-3-phenylprop-2-ynamide having derivatives thereof which can repress (prevent or treat) a symptom of vibrio infection by inhibiting RTX toxin production, other than directly killing vibrio bacteria, to not allow vibrio bacteria to have pathogenicity, and thereby can be an alternative to antibiotics that aim to kill bacteria themselves and thus fundamentally retain the problem of resistance incurrence.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 29, 2022
    Inventors: Sang Ho Choi, Lak Shin Jeong, Ho Jae Han, Nam Chul Ha, Byoung Sik Kim, Kyung Ku Jang, Zee-Won Lee
  • Patent number: 11485709
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: November 1, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
  • Patent number: 11458123
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: October 4, 2022
    Inventors: Andrew P. Crew, Michael Berlin, Hanqing Dong, Alexey Ishchenko
  • Patent number: 11459295
    Abstract: The invention includes 2-?-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are (R)-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 4, 2022
    Inventors: Trevor M. Penning, Adegoke Adeniji, Lawrence J. Marnett
  • Patent number: 11434228
    Abstract: The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: September 6, 2022
    Assignee: LT MATERIALS CO., LTD.
    Inventors: Gi-Back Lee, Seong-Jong Park, Ji-Young Kim, Won-Jang Jeong, Jin-Seok Choi, Dae-Hyuk Choi, Joo-Dong Lee
  • Patent number: 11426411
    Abstract: The invention is directed to a method of treatment for inflammation in mammals including inflammation caused by bacterial or viral infection, the method comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 30, 2022
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard, Andrew Morgan Stewart
  • Patent number: 11427861
    Abstract: The present invention provides tools and methods for the systematic analysis of genetic interactions between cells. The present invention provides tools and methods for modulating cell phenotypes and compositions, combinatorial probing of cellular circuits, for dissecting cellular circuitry, for delineating molecular pathways, and/or for identifying relevant targets for therapeutics development.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 30, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Alexander K. Shalek, Alexander S. Genshaft, Carly G. K. Ziegler, Jeffrey F. Van Humbeck
  • Patent number: 11414432
    Abstract: The present invention relates to novel fused bicyclic heterocycle derivatives of formula (I) in which B1, B2, B3, B4, R1, R4, R5, R6 and n have the meanings mentioned above, to agrochemical formulations comprising the compounds of formula (I) and to their use as acaricides and/or insecticides for controlling animal pests, especially arthropods and in particular insects and arachnids.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 16, 2022
    Inventors: Dominik Hager, Ruediger Fischer, Laura Hoffmeister, Matthieu Willot, Kerstin Ilg, Ulrich Goergens
  • Patent number: 11407727
    Abstract: Disclosed are compounds, for example, compounds of formula I, wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: August 9, 2022
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • Patent number: 11401265
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: August 2, 2022
    Inventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
  • Patent number: 11400073
    Abstract: A method of preventing and/or treating disease in which reactive oxygen species (or ROSs) of mitochondrial origin are involved. The method involves use of an inhibitor of mitochondrial ROS production, in particular, of anethole trithione, for the prevention and/or treatment of benign prostatic hyperplasia.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 2, 2022
    Inventor: Olivier Petitjean
  • Patent number: 11382971
    Abstract: Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: July 12, 2022
    Assignee: Tsinghua University
    Inventors: Yonghui Zhang, Yun Xia, Yonghua Xie, Zhengsen Yu, Xiaoying Zhou, Xin Li, Liping Li, Yunyun Yang, Kanzhao Gao, Ke Wang, Wanli Liu, Meng Zhao
  • Patent number: 11387414
    Abstract: The present invention relates to spirobifluorene compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 12, 2022
    Inventors: Elvira Montenegro, Amir Hossain Parham, Philipp Stoessel, Teresa Mujica-Fernaud, Frank Voges, Arne Buesing
  • Patent number: 11384093
    Abstract: This invention relates to a process for preparing (±)-2-exo-(2-Methylbenzyloxy)-1-methyl-4-iso-propyl-7-oxabicyclo[2.2.1]heptane of the formula (I) any of its individual enantiomers or any non-racemic mixture thereof, comprising the step of reacting (±)-2-exo-hydroxy-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (II) any of its individual enantiomers or any non-racemic mixture thereof with a 2-Methylbenzyl compound of the formula (III) wherein X is a leaving group, in the presence of at least one base, at least one catalyst selected from rubidium salts, cesium salts and any combination thereof and at least one inert organic solvent S1.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 12, 2022
    Assignee: BASF AGRO B.V.
    Inventors: Stefan Benson, Michael Rack, Christiane Alznauer, Roland Goetz, Bernd Wolf